Please login to the form below

Not currently logged in
Email:
Password:

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

Scot Harper, Endocyte Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma company.

Dr Harper (pictured right) joins from clinical research organisation (CRO) Parexel, where he held the role of global portfolio director for oncology, overseeing clinical activities for cancer drugs from phase I to IV development.

He also has experience working in clinical operations for major pharma companies, serving as VP of Novartis' North American clinical operations, and senior director of clinical operations at Lilly.

Prior to this, Dr Harper worked in new product development at SmithKline Beechham.

Endocyte, which focuses on developing therapies for the treatment of cancer and other serious diseases, will benefit from his experience of working on the development of major oncology brands like Tasigna and Gleevec.

“Scot has deep expertise in the drug development process and management of all stages of clinical trials, and he will play a key role at Endocyte as we seek to expand and advance our platform,” said Ron Ellis, Endocyte's president and CEO, referencing the development of oncology candidates vintafolide and etarfolatide, which are in phase III and phase II trials respectively.

In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.

9th May 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics